It is a fully human monoclonal antibody that targets human PD-L1, with the IgG1 isotype.

IMC-001 binds to PD-L1 on the surface of cancer cells, which blocks the interaction between PD-1 and PD-L1. This action increases the anti-cancer activity of T-cells. Furthermore, it activates antibody-dependent cellular cytotoxicity (ADCC) from NK cells, which induces the death of cancer cells.